Welcome to our dedicated page for Aardvark Therapeutics news (Ticker: AARD), a resource for investors and traders seeking the latest updates and insights on Aardvark Therapeutics stock.
Aardvark Therapeutics (AARD) is a clinical-stage biopharmaceutical company pioneering novel therapies for metabolic diseases through targeted activation of gut-based receptors. This page serves as the definitive source for verified news and official announcements related to their research programs, clinical developments, and corporate milestones.
Investors and researchers will find timely updates on clinical trial progress, regulatory designations, and scientific partnerships, including developments in their lead candidate ARD-101 for hyperphagia management. The curated news collection provides essential context about their unique approach to appetite regulation through TAS2R-targeted therapeutics.
All content undergoes rigorous verification to ensure accuracy, with focus areas including trial phase advancements, peer-reviewed research citations, and strategic collaborations. Regular updates reflect the company's progress in addressing rare metabolic disorders while maintaining compliance with financial disclosure standards.
Bookmark this page for direct access to primary source updates about Aardvark's innovative pipeline and regulatory milestones. For comprehensive tracking of this clinical-stage biopharma's progress, consider subscribing to Stock Titan's news alerts.
Aardvark Therapeutics (NASDAQ: AARD) reported its full year 2024 financial results and business highlights. The company's lead candidate ARD-101 showed promising results in a Phase 2 trial for Prader-Willi Syndrome (PWS), demonstrating up to 16-point HQ-CT reduction in hyperphagia and improvements in body composition over 28 days.
The company successfully completed its IPO in February 2025, raising $97.9 million in gross proceeds. Financial results show cash position of $73.7 million as of December 31, 2024. R&D expenses increased to $17.4 million from $4.5 million in 2023, while G&A expenses rose to $5.3 million from $2.2 million. Net loss widened to $20.6 million from $7.2 million in 2023.
Key upcoming milestones include Phase 2 HONOR trial initiation for hypothalamic obesity and Phase 2 EMPOWER trial for ARD-201 in H2 2025, with Phase 3 HERO trial topline data expected in early 2026.
Aardvark Therapeutics (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for metabolic diseases, has announced the pricing of its initial public offering. The company is offering 5,888,000 shares of common stock at $16.00 per share, expecting to raise gross proceeds of approximately $94.2 million.
Trading is set to commence on the Nasdaq Global Select Market on February 13, 2025, under the ticker symbol 'AARD'. The offering is expected to close on February 14, 2025. Additionally, underwriters have a 30-day option to purchase up to 883,200 additional shares at the public offering price. Morgan Stanley, BofA Securities, Cantor, and RBC Capital Markets are serving as joint book-running managers for the IPO.
